4-(3-chloroindol-7-ylamino)-7-(2-hydroxy-3-morpholinopropoxy)-6-methoxyquinazoline | 418811-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(3-chloroindol-7-ylamino)-7-(2-hydroxy-3-morpholinopropoxy)-6-methoxyquinazoline
• 英文别名: 1-[4-[(3-chloro-1H-indol-7-yl)amino]-6-methoxyquinazolin-7-yl]oxy-3-morpholin-4-ylpropan-2-ol
• CAS: 418811-87-7
• 化学式: C₂₄H₂₆ClN₅O₄
• 分子量: 483.955
• InChiKey: MSTGRCFZNCIFDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  7-(2-Acetoxy-3-morpholinopropoxy)-4-(3-chloroindol-7-ylamino)-6-methoxyquinazoline dihydrochloride 、 氨 、 、 盐酸 、 乙醚 在 NH2 silica 、 二氯甲烷 、 甲醇 、 resultant precipitate 、 乙醚 、 hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 反应 72.0h， 以There was thus obtained the title compound (0.052 g) as a dihydrochloride salt的产率得到4-(3-chloroindol-7-ylamino)-7-(2-hydroxy-3-morpholinopropoxy)-6-methoxyquinazoline
  参考文献：
  名称：

  Quinazoline derivatives

  摘要：

  本发明涉及公式I1的喹噁啉衍生物，其中m、R1、n、R2和R3中的每一个都具有描述中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于抗侵袭剂在固体肿瘤病的控制和/或治疗中使用的药物的用途。

  公开号：

  US20040063733A1

文献信息

• Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine
  申请人：Barge Alan

  公开号：US20060142297A1

  公开（公告）日：2006-06-29

  The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent gemcitabine, a pharmaceutical composition comprising such a combination and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer.

  本发明涉及一种组合物，包括Src激酶抑制剂和细胞毒素吉西他滨，一种含有该组合物的药物组合物以及其在治疗或预防癌症，特别是胰腺癌方面的用途。
• QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1332141A1

  公开（公告）日：2003-08-06
• COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER
  申请人：AstraZeneca AB

  公开号：EP1562612B1

  公开（公告）日：2010-01-27
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2002034744A1

  公开（公告）日：2002-05-02

  The invention concerns quinazoline derivatives of the formula (I) wherein each of m, R?1, n, R2 and R3¿ have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
• [EN] THERAPEUTIC AGENT<br/>[FR] AGENT THERAPEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2004087120A2

  公开（公告）日：2004-10-14

  The invention relates to the use of a Src kinase inhibitor in the production of a medicament for use in the prophylaxis or treatment of hypertension. More particularly, the invention concerns the anti-hypertensive use of a selective Src kinase inhibitor that possess less potent VEGF receptor tyrosine kinase inhibitory properties. The invention also relates to a combination product comprising a Src kinase inhibitor and one or more further anti-hypertensive agents and to the use of Src kinase inhibitors as primary regulators of cardiovascular disease and in the prevention of stroke.